Trial Profile
A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms BRIGHTER
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 14 Jul 2022 Results published in the Clinical Cancer Research
- 26 May 2022 Results published in the Clinical Cancer Research
- 30 Sep 2019 Status changed from active, no longer recruiting to completed.